AstraZeneca Receives European Commission Clearance For Acquisition Of Alexion Pharma
AstraZeneca's proposed acquisition of Alexion Pharmaceuticals, (Alexion) has achieved an important step towards completion by having cleared the European Commission (EC) review.The clearance follows competition clearances in the United States, Japan and other countries globally, with a complete list available on astrazeneca.com. Regulatory clearance in the UK is pending and remains a requirement to complete the deal.Marc Dunoyer, executive director and chief financial officer, said: “We are pleased to have secured clearance from the European Commission for the proposed acquisition of Alexion, a pioneer in the discovery and development of medicines for rare diseases. We are now another step closer to closing the acquisition and combining the two companies to create a leader in immunology and precision medicines. We continue to progress towards the completion of the acquisition during this quarter.”The proposed acquisition, first announced in December 2020, would enhance the Company's scientific presence in immunology by adding Alexion's innovative complement-technology platform and an extensive pipeline. Rare diseases represent a high-growth disease area with rapid innovation and significant unmet medical needs. Shareholders of both companies overwhelmingly supported the acquisition by their votes on 11 May 2021.Subject to completing the acquisition, a group focusing on rare diseases will be created. This group will be named ‘Alexion, AstraZeneca Rare Disease’, and will be headquartered in Boston, US.Over 7,000 rare diseases are known today, and only approximately 5% have treatments approved by the US Food and Drug Administration. Demand in medicines for rare diseases is forecasted to grow by a low double-digit percentage in the future.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!